RT Journal Article
SR Electronic
T1 1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A1132
OP A1132
DO 10.1136/jitc-2023-SITC2023.1024
VO 11
IS Suppl 1
A1 Meetze, Kristan A
A1 Mehta, Naveen K
A1 Michaelson, Jennifer S
A1 Baeuerle, Patrick A
A1 Findlay, Hannah M
A1 London, Timothy B
A1 Patakas, Agapitos
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A1132.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.